A Single-blind, Randomized, Placebo Controlled, Two-period Crossover fMRI Study to Investigate the Effects of the D3 Antagonist GSK598809 on Neural and Behavioural Responses to Food Reward and Reinforcement After a Single Oral Dose of GSK598809 in Overweight and Obese Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2016
At a glance
- Drugs GSK 598809 (Primary)
- Indications Eating disorders; Obesity
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 07 Dec 2016 Last checked against ClinicalTrials.gov record.
- 12 Jul 2011 Results published in the International Journal of Neuropsychopharmacology.